Juan C. Celedón, MD, DrPh, from the University of Pittsburgh, answers our questions about his research on omics in childhood asthma—a topic he has also spoken about at the Celebration of Pediatric...
In this article, Scott T. Vergano, MD, writes about 4 papers you may have missed in May 2022, including a rescue medication recommendation, differentiating Bell’s palsy from Lyme-related facial palsy,...
Researchers examined how airway differentiation of eosinophilic progenitor cells may impact non-asthmatic eosinophilic bronchitis and eosinophilic asthma.
A recent study presented at CHEST2020 examined updates to the severe asthma treatment guidelines concerning non-Th2 asthma. Lead author, Diego J. Maselli, MD, FCCP answered our questions about his team’s...
Allen J. Dozor, MD, from New York Medical College, answers our questions about his work in developing high-risk asthma programs, and explains how other practitioners can implement similar programs.
Sandhya Khurana, MD, from the University of Rochester, answers our questions about evidence-based best practices when addressing the special needs of patients with severe asthma.
In this podcast, Michael Peters, MD, talks about his team's cross-sectional analysis on the use of blood eosinophils and IL-6 as predictive biomarkers of the exacerbation-prone asthma phenotype over 3...
In this podcast, Shervin S. Takyar, MD, PhD, from Yale School of Medicine, answers our questions about how microRNA-1 regulates eosinophil trafficking in patients with asthma and chronic...
Prednisone is a prodrug. Prednisone is a glucocorticoid. Prednisone is a mineralocorticoid. But is prednisone a poison? What have patients taught us about prednisone?
The lead authors of a new study about the 20-year financial and health burdens of asthma—J. Mark FitzGerald, MD, and Mohsen Sadatsafavi, MD, PhD—answer our questions about its findings.
